Impact of Antenatal Betamethasone on Plasma Glucose Levels
1 other identifier
observational
45
1 country
1
Brief Summary
It is known that administration of steroids increases blood sugar levels. Administration of betamethasone is common practice during pregnancy to women at risk for preterm delivery. However, it is unknown the magnitude of the changes in glucose these women have after receiving betamethasone. The purpose of this study is to determine the magnitude and timing of the increase in blood sugar in pregnant women without diabetes who receive steroids.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Nov 2007
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2007
CompletedFirst Submitted
Initial submission to the registry
January 2, 2008
CompletedFirst Posted
Study publicly available on registry
January 3, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2011
CompletedFebruary 27, 2019
February 1, 2019
3.5 years
January 2, 2008
February 26, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Area under the curve of blood glucose
5 days
Study Arms (3)
Diabetic
Patients with Diabetes
Abnormal glucose level
Patients who were screened and had abnormal blood glucose levels
Control
Non-diabetic (normal glucose screening)
Eligibility Criteria
Pregnant women receiving corticosteroids
You may qualify if:
- Candidates for antenatal corticosteroids (including gestational age between 24-34 weeks)
You may not qualify if:
- Age less than 18 years
- Pre-existing maternal corticosteroid or beta-mimetic tocolytic use
- Pre-gestational diabetes mellitus, class C or greater
- Pre-existing adrenal or pancreatic dysfunction
- Evidence of infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of California, Irvinelead
- University of Washingtoncollaborator
Study Sites (1)
Miller Children's Hospital
Long Beach, California, 90806, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael P Nageotte, MD
Miller Children's Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor and Director, Maternal-Fetal Medicine
Study Record Dates
First Submitted
January 2, 2008
First Posted
January 3, 2008
Study Start
November 1, 2007
Primary Completion
May 1, 2011
Study Completion
May 1, 2011
Last Updated
February 27, 2019
Record last verified: 2019-02